AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback  Announced positive updated results from the company’s expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% treatment success at the end of therapy  Raised gross proceeds of $6.8 million through an […]

AmpliPhi Biosciences Announces Closing of Public Offering

Tuesday, October 16, 2018 4:10 pm EDT PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the closing of its previously announced underwritten public offering. Gross proceeds to AmpliPhi from […]

AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

CATEGORY: Featured Friday, October 12, 2018 6:00 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten public offering of 16,537,500 […]

AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

 13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhi’s expanded access program  Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthetic valve endocarditis  83% (10 out of 12) patients in the modified intent-to-treat (mITT) population achieved treatment success […]

AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018

Professor Jonathan Iredell to present data from AmpliPhi Biosciences’ ongoing expanded access program for bacteriophage product candidates AB-SA01 (targeting S. aureus) and AB-PA01 (targeting P. aeruginosa) Monday, September 24, 2018 6:50 am EDT PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics […]

AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections

The FDA is in general agreement with the design of two proposed randomized clinical trials of AB-PA01, hospital-acquired and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa and for P. aeruginosa bacteremia, and no additional preclinical or clinical data are required to proceed with both trials  Based on the positive FDA feedback, AmpliPhi intends to seek […]

AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01

 FDA is in general agreement with the design of two proposed randomized clinical trials of AB-SA01, for Staphylococcus aureus bacteremia and prosthetic joint infections, and no additional preclinical or clinical data are required to proceed with both trials  AmpliPhi expects to initiate one of these clinical trials in early 2019  AmpliPhi continues to investigate if […]

AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program

21 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have now been treated with AB-SA01 (targeting S. aureus) or AB-PA01 (targeting P. aeruginosa) under AmpliPhi’s expanded access program Over 1,000 doses of bacteriophage product candidates, AB-SA01 or AB-PA01, have been administered as part of the expanded access program since mid-2017 […]

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

“These case studies indicate that AB-SA01 may be safely administered intravenously in the critically ill and may have a role to play in the management of severe staphylococcal sepsis, for patients with resistant and life-threatening infections” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for […]

AmpliPhi Biosciences Announces Presentation of AB-PA01 Bacteriophage Therapy Case Study at 41st European Cystic Fibrosis Conference

PUBLIC COMPANY INFORMATION: “Furthermore, treatment with AB-PA01 was safe and well-tolerated. In this case study, bacteriophage therapy has demonstrated to hold much promise for patients with cystic fibrosis suffering from multidrug resistant pulmonary bacterial infections.” AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today […]